for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alector Inc

ALEC.OQ

現在値

23.61USD

変化

-0.12(-0.51%)

出来高

131,186

本日のレンジ

22.91

 - 

23.95

52週レンジ

9.18

 - 

43.30

∙ 約20分前の相場を表示しています。

適時開示

Alector Reports Q2 2021 Financial Results

Aug 3 (Reuters) - Alector Inc <ALEC.O>::ALECTOR REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS.COLLABORATION REVENUE FOR QUARTER ENDED JUNE 30, 2021, WAS $6.6 MILLION, COMPARED TO $3.2 MILLION.ALECTOR ANTICIPATES SUFFICIENT CASH TO FUND CURRENTLY PLANNED OPERATIONS INTO MID-2024.QTRLY LOSS PER SHARE $0.69.Q2 EARNINGS PER SHARE VIEW $-0.68, REVENUE VIEW $8.7 MILLION -- REFINITIV IBES DATA.

Alector Presents 12-Month Results From The Infront-2 Phase 2 Open-Label Clinical Study Of Al001 For The Treatment Of Symptomatic Frontotemporal Dementia Patients With A Progranulin Mutation

July 29 (Reuters) - Alector Inc <ALEC.O>::ALECTOR PRESENTS 12-MONTH RESULTS FROM THE INFRONT-2 PHASE 2 OPEN-LABEL CLINICAL STUDY OF AL001 FOR THE TREATMENT OF SYMPTOMATIC FRONTOTEMPORAL DEMENTIA PATIENTS WITH A PROGRANULIN MUTATION.ALECTOR INC - AL001 SUCCESSFULLY RESTORED PROGRANULIN TO NORMAL LEVELS IN FTD-GRN PATIENTS.ALECTOR INC - TREATMENT WITH AL001 SLOWED CLINICAL PROGRESSION BY 47% BASED ON CDR PLUS NACC FTLD-SB SCALE RELATIVE TO GENFI2 MATCHED CONTROL COHORT.ALECTOR INC - CONSISTENT TRENDS TOWARD NORMALIZATION OR STABILIZATION INMULTIPLE DISEASE BIOMARKERS OBSERVED WITH AL001 TREATMENT.ALECTOR INC - AL001 SHOWED A FAVORABLE SAFETY PROFILE IN PHASE 2 OPEN-LABEL CLINICAL STUDY.

Alector Reports Q1 Loss Per Share Of $0.66

May 5 (Reuters) - Alector Inc <ALEC.O>::ALECTOR REPORTS 2021 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.COLLABORATION REVENUE FOR QUARTER ENDED MARCH 31, 2021, WAS $4.1 MILLION, COMPARED TO $7.2 MILLION FOR SAME PERIOD IN 2020..QTRLY LOSS PER SHARE $0.66.Q1 EARNINGS PER SHARE VIEW $-0.69 -- REFINITIV IBES DATA.

Alector Reports 2020 Q4 And Full Year Financial Results

Feb 25 (Reuters) - Alector Inc <ALEC.O>::ALECTOR REPORTS 2020 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.ALECTOR INC - QTRLY LOSS PER SHARE $0.66.

Alector Provides 2021 Corporate Portfolio Update

Jan 7 (Reuters) - Alector Inc <ALEC.O>::ALECTOR PROVIDES 2021 CORPORATE PORTFOLIO UPDATE.ALECTOR INC - UPDATED DATA FROM ONGOING AL001 PHASE 2 STUDY IN FRONTOTEMPORAL DEMENTIA EXPECTED IN 2021.ALECTOR INC - CLINICAL TRIALS ADVANCING FOR PHASE 3 IN FRONTOTEMPORAL DEMENTIA AND PHASE 2 IN ALZHEIMER'S DISEASE.ALECTOR INC - MORE THAN $400 MILLION IN CASH ON BALANCE SHEET.

Alector On Track To Initiate Phase 2 Study For AL002 In Alzheimer's Disease In 2020

Nov 10 (Reuters) - Alector Inc <ALEC.O>::ALECTOR REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ALECTOR INC - ON TRACK TO INITIATE PHASE 2 STUDY FOR AL002 IN ALZHEIMER'S DISEASE IN 2020.ALECTOR INC - QTRLY LOSS PER SHARE $0.67.ALECTOR INC - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $461.7 MILLION AS OF SEPTEMBER 30, 2020.ALECTOR - BELIEVES CASH, INVESTMENTS AS OF SEPT 30, TO BE SUFFICIENT TO FUND ANTICIPATED OPERATIONS THROUGH 2022.

Alector Provides Update On Arbitration Proceedings With Dr. ASA Abeliovich

Nov 2 (Reuters) - Alector Inc <ALEC.O>::ALECTOR PROVIDES UPDATE ON ARBITRATION PROCEEDINGS WITH DR. ASA ABELIOVICH.ALECTOR INC - INDEPENDENT ARBITRATOR FINDS IN FAVOR OF ALECTOR IN CONFIDENTIAL ARBITRATION PROCEEDINGS.ALECTOR INC - DR. ABELIOVICH REMAINS BOUND BY CONTRACTUAL OBLIGATIONS RELATED TO CONFIDENTIALITY OF COMPANY'S INTELLECTUAL PROPERTY RIGHTS.ALECTOR INC - DETAILS RELATING TO ARBITRATION PROCEEDING AND ITS OUTCOME ARE CONFIDENTIAL..

Alector Reports Second Quarter 2020 Financial Results And Provides Corporate Update

Alector Inc <ALEC.O>::ALECTOR REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ALECTOR INC - AL002, AL003 AND AL014 PROGRAMS FOR TREATMENT OF ALZHEIMER'S DISEASE AND AL101 NEUROLOGY PROGRAM CONTINUE TO PROGRESS.ALECTOR INC - PROMISING PRELIMINARY DATA FROM AL001 PHASE 1B AND PHASE 2 OPEN-LABEL STUDIES.ALECTOR INC - PLANS TO INITIATE PHASE 1 DEVELOPMENT FOR AL014 IN FIRST HALF OF 2021.ALECTOR INC - QTRLY LOSS PER SHARE $0.58.ALECTOR INC - COLLABORATION REVENUE FOR QUARTER WAS $3.2 MILLION VERSUS $6.9 MILLION.

Alector Plans To Present Additional Phase 2 Data Highlighting Clinical & Biomarker Endpoints In Future

July 28 (Reuters) - Alector Inc <ALEC.O>::ALECTOR ANNOUNCES PROMISING PRELIMINARY DATA FROM AL001 PHASE 1B AND PHASE 2 OPEN-LABEL LONG-TERM DOSING STUDY OF PEOPLE WITH FRONTOTEMPORAL DEMENTIA.ALECTOR INC - PIVOTAL PHASE 3 STUDY INITIATED IN JULY 2020.ALECTOR -TREATMENT WITH AL001 IN PHASE 2 STUDY RESULTED IN SUSTAINED RESTORATION OF PLASMA PROGRANULIN LEVELS IN FTD-GRN PATIENTS BACK TO NORMAL RANGE.ALECTOR - IN PHASE 2 STUDY, MAJORITY OF SYMPTOMATIC FTD-GRN PARTICIPANTS SHOWED A DECREASE IN PLASMA NEUROFILAMENT LIGHT CHAIN LEVELS FROM BASELINE.ALECTOR INC - AL001 WAS GENERALLY SAFE AND WELL-TOLERATED IN PHASE 1B STUDY.ALECTOR - DUE TO COVID-19, SEVERAL CLINICAL SITES FOR PHASE 2 STUDY WERE TEMPORARILY CLOSED OR CONDUCTED REDUCED OR REMOTE PATIENT ASSESSMENTS.ALECTOR - EARLY DATA SUGGEST LONGER TERM TREATMENT WITH AL001 COULD LEAD TO SUSTAINED INCREASE IN PGRN & SUSTAINED REDUCTION IN PLASMA NFL OVER TIME.ALECTOR INC - PLANS TO PRESENT ADDITIONAL PHASE 2 DATA HIGHLIGHTING CLINICAL & BIOMARKER ENDPOINTS IN FUTURE.

Alector Says Orbimed Advisors Cuts Share Stake In Co To 3.5% From 7.0%

July 16 (Reuters) - Alector Inc <ALEC.O>::ORBIMED ADVISORS LLC CUTS SHARE STAKE IN ALECTOR INC TO 3.5% AS OF JULY 14 FROM A STAKE OF 7.0% AS OF JULY 7 - SEC FILING.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up